| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 31 | 2025 | 3447 | 5.310 |
Why?
|
| Blood Glucose Self-Monitoring | 20 | 2024 | 475 | 3.940 |
Why?
|
| Hypoglycemia | 14 | 2024 | 895 | 2.910 |
Why?
|
| Blood Glucose | 33 | 2024 | 6431 | 2.380 |
Why?
|
| Insulin | 29 | 2024 | 6610 | 1.830 |
Why?
|
| Hypoglycemic Agents | 18 | 2024 | 3109 | 1.530 |
Why?
|
| Insulin Infusion Systems | 11 | 2024 | 221 | 1.140 |
Why?
|
| Diabetes Complications | 2 | 2023 | 1320 | 1.000 |
Why?
|
| Postprandial Period | 3 | 2024 | 320 | 0.800 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 5 | 2016 | 120 | 0.730 |
Why?
|
| HIV Protease Inhibitors | 6 | 2011 | 430 | 0.680 |
Why?
|
| Sarcoma, Kaposi | 9 | 2009 | 376 | 0.660 |
Why?
|
| Self Care | 3 | 2023 | 799 | 0.600 |
Why?
|
| Matrix Metalloproteinase 2 | 8 | 2011 | 462 | 0.560 |
Why?
|
| Injections | 1 | 2019 | 841 | 0.510 |
Why?
|
| Telemedicine | 2 | 2023 | 3109 | 0.500 |
Why?
|
| Gene Products, tat | 3 | 2006 | 111 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 2 | 11 | 2020 | 12252 | 0.470 |
Why?
|
| Insulin-Secreting Cells | 6 | 2011 | 899 | 0.400 |
Why?
|
| Biosensing Techniques | 1 | 2018 | 662 | 0.390 |
Why?
|
| Diabetes Mellitus | 4 | 2024 | 5891 | 0.310 |
Why?
|
| HIV-1 | 6 | 2016 | 6963 | 0.310 |
Why?
|
| Islets of Langerhans | 8 | 2011 | 1351 | 0.300 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 2237 | 0.290 |
Why?
|
| Aging | 4 | 2023 | 8743 | 0.290 |
Why?
|
| Medication Adherence | 1 | 2019 | 2187 | 0.280 |
Why?
|
| Aged | 26 | 2024 | 171502 | 0.270 |
Why?
|
| Humans | 95 | 2025 | 768171 | 0.270 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 3948 | 0.260 |
Why?
|
| Dietary Carbohydrates | 2 | 2024 | 896 | 0.260 |
Why?
|
| Indinavir | 4 | 2011 | 73 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2006 | 474 | 0.230 |
Why?
|
| Benchmarking | 2 | 2022 | 1057 | 0.230 |
Why?
|
| Dendritic Cells | 5 | 2017 | 2747 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 478 | 0.230 |
Why?
|
| Uridine Triphosphate | 1 | 2023 | 29 | 0.230 |
Why?
|
| Interferon-alpha | 3 | 2017 | 910 | 0.230 |
Why?
|
| Glycemic Index | 2 | 2024 | 400 | 0.220 |
Why?
|
| Neovascularization, Pathologic | 4 | 2011 | 2631 | 0.210 |
Why?
|
| Young Adult | 11 | 2025 | 60066 | 0.210 |
Why?
|
| Peptide Fragments | 1 | 2016 | 5151 | 0.210 |
Why?
|
| Dental Cavity Lining | 2 | 1993 | 3 | 0.210 |
Why?
|
| Immunization, Passive | 2 | 2022 | 619 | 0.200 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 4055 | 0.200 |
Why?
|
| Aged, 80 and over | 8 | 2023 | 59626 | 0.190 |
Why?
|
| Adult | 38 | 2025 | 223646 | 0.190 |
Why?
|
| Middle Aged | 34 | 2024 | 223487 | 0.180 |
Why?
|
| Metalloendopeptidases | 2 | 2001 | 386 | 0.180 |
Why?
|
| Glucose | 6 | 2021 | 4352 | 0.180 |
Why?
|
| ras Proteins | 1 | 2006 | 1058 | 0.180 |
Why?
|
| Matrix Metalloproteinase 9 | 4 | 2011 | 634 | 0.180 |
Why?
|
| Dog Diseases | 1 | 2021 | 143 | 0.170 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2002 | 594 | 0.170 |
Why?
|
| Pancreas | 2 | 2010 | 1699 | 0.170 |
Why?
|
| Technology | 1 | 2022 | 296 | 0.160 |
Why?
|
| Community Networks | 1 | 2021 | 202 | 0.160 |
Why?
|
| Quality of Life | 6 | 2025 | 13490 | 0.160 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2002 | 664 | 0.160 |
Why?
|
| beta-Lactamases | 1 | 2021 | 307 | 0.160 |
Why?
|
| Saquinavir | 3 | 2011 | 29 | 0.160 |
Why?
|
| Pandemics | 3 | 2023 | 8747 | 0.150 |
Why?
|
| Neoplasms | 4 | 2019 | 22371 | 0.150 |
Why?
|
| Italy | 6 | 2021 | 856 | 0.150 |
Why?
|
| Plasma | 1 | 2021 | 585 | 0.150 |
Why?
|
| Dental Restoration, Permanent | 3 | 1993 | 130 | 0.150 |
Why?
|
| Anti-Obesity Agents | 1 | 2021 | 240 | 0.150 |
Why?
|
| Female | 42 | 2025 | 397187 | 0.150 |
Why?
|
| Endothelium, Vascular | 5 | 2005 | 4428 | 0.150 |
Why?
|
| Male | 41 | 2024 | 364731 | 0.150 |
Why?
|
| Genes, p53 | 1 | 2000 | 714 | 0.150 |
Why?
|
| Pilot Projects | 2 | 2023 | 8741 | 0.150 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 1741 | 0.140 |
Why?
|
| Glucagon | 2 | 2018 | 535 | 0.140 |
Why?
|
| Escherichia coli Infections | 1 | 2021 | 524 | 0.140 |
Why?
|
| Patient Education as Topic | 3 | 2024 | 2337 | 0.130 |
Why?
|
| Diabetic Neuropathies | 1 | 2020 | 410 | 0.130 |
Why?
|
| Cell Tracking | 1 | 2017 | 140 | 0.130 |
Why?
|
| Viral Regulatory and Accessory Proteins | 1 | 2016 | 151 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2002 | 2057 | 0.130 |
Why?
|
| Hyperglycemia | 2 | 2017 | 1388 | 0.120 |
Why?
|
| Dentin | 3 | 1991 | 75 | 0.120 |
Why?
|
| Liver Regeneration | 1 | 2016 | 214 | 0.120 |
Why?
|
| Pancreatic Ducts | 2 | 2008 | 330 | 0.110 |
Why?
|
| Oxalates | 2 | 1991 | 99 | 0.110 |
Why?
|
| Glass Ionomer Cements | 1 | 1993 | 18 | 0.110 |
Why?
|
| Dental Occlusion | 1 | 1993 | 54 | 0.110 |
Why?
|
| Dental Amalgam | 1 | 1993 | 65 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2017 | 11878 | 0.110 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2021 | 1063 | 0.110 |
Why?
|
| HIV Infections | 6 | 2016 | 17569 | 0.110 |
Why?
|
| Age Factors | 2 | 2020 | 18415 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 1240 | 0.100 |
Why?
|
| Mice, Nude | 4 | 2011 | 3623 | 0.100 |
Why?
|
| Circadian Rhythm | 2 | 2001 | 2593 | 0.100 |
Why?
|
| Hepatectomy | 1 | 2016 | 588 | 0.100 |
Why?
|
| Cell Movement | 5 | 2011 | 5213 | 0.100 |
Why?
|
| Microfluidics | 1 | 2017 | 672 | 0.100 |
Why?
|
| Adolescent | 7 | 2025 | 89169 | 0.090 |
Why?
|
| Maf Transcription Factors, Large | 1 | 2010 | 21 | 0.090 |
Why?
|
| C-Peptide | 3 | 2002 | 443 | 0.090 |
Why?
|
| HMGB1 Protein | 1 | 2012 | 141 | 0.090 |
Why?
|
| Dietary Proteins | 1 | 2016 | 960 | 0.090 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2004 | 1903 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2024 | 5536 | 0.090 |
Why?
|
| Dental Materials | 1 | 1991 | 113 | 0.090 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 561 | 0.090 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 614 | 0.090 |
Why?
|
| Overweight | 1 | 2021 | 2448 | 0.090 |
Why?
|
| Peptides, Cyclic | 1 | 2012 | 391 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2020 | 2709 | 0.090 |
Why?
|
| Bacterial Proteins | 2 | 2021 | 3840 | 0.090 |
Why?
|
| Keratin-19 | 1 | 2010 | 33 | 0.090 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2010 | 49 | 0.090 |
Why?
|
| Gluconeogenesis | 2 | 2001 | 185 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 7852 | 0.080 |
Why?
|
| env Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 381 | 0.080 |
Why?
|
| Integrins | 2 | 2012 | 842 | 0.080 |
Why?
|
| Enzyme Activation | 3 | 2006 | 3590 | 0.080 |
Why?
|
| Nitroprusside | 4 | 2006 | 272 | 0.080 |
Why?
|
| Blood Flow Velocity | 4 | 2006 | 1375 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 3 | 2011 | 6231 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 10763 | 0.080 |
Why?
|
| Taxoids | 1 | 2012 | 667 | 0.080 |
Why?
|
| Retrospective Studies | 5 | 2021 | 81760 | 0.080 |
Why?
|
| Escherichia coli | 1 | 2021 | 4213 | 0.080 |
Why?
|
| Insulin Resistance | 6 | 2007 | 3986 | 0.080 |
Why?
|
| Herpesvirus 8, Human | 2 | 2009 | 256 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2020 | 41753 | 0.080 |
Why?
|
| Dietary Fats | 1 | 2016 | 2003 | 0.080 |
Why?
|
| Forearm | 4 | 2006 | 427 | 0.080 |
Why?
|
| Matrix Metalloproteinases | 1 | 2011 | 393 | 0.080 |
Why?
|
| Decision Support Techniques | 1 | 2018 | 2008 | 0.080 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 1351 | 0.070 |
Why?
|
| Drug Discovery | 1 | 2016 | 1068 | 0.070 |
Why?
|
| Models, Biological | 5 | 2017 | 9497 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2021 | 5349 | 0.070 |
Why?
|
| Anti-HIV Agents | 3 | 2016 | 4573 | 0.070 |
Why?
|
| Obesity | 5 | 2021 | 13091 | 0.070 |
Why?
|
| Mouth Diseases | 1 | 1989 | 239 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2018 | 5315 | 0.070 |
Why?
|
| Cell Transdifferentiation | 1 | 2008 | 186 | 0.070 |
Why?
|
| Endocytosis | 1 | 2011 | 957 | 0.070 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 3612 | 0.070 |
Why?
|
| Colorectal Neoplasms | 2 | 2017 | 6975 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 10397 | 0.070 |
Why?
|
| Shc Signaling Adaptor Proteins | 1 | 2006 | 46 | 0.070 |
Why?
|
| Depsipeptides | 2 | 2017 | 96 | 0.070 |
Why?
|
| GRB2 Adaptor Protein | 1 | 2006 | 101 | 0.060 |
Why?
|
| Thyroiditis, Autoimmune | 2 | 1999 | 101 | 0.060 |
Why?
|
| Cells, Cultured | 7 | 2017 | 19025 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 4648 | 0.060 |
Why?
|
| HIV Antibodies | 1 | 2012 | 1341 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2016 | 10478 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 26379 | 0.060 |
Why?
|
| Herpesviridae Infections | 1 | 2007 | 269 | 0.060 |
Why?
|
| Homeodomain Proteins | 2 | 2006 | 2430 | 0.060 |
Why?
|
| Oligopeptides | 2 | 2012 | 1194 | 0.060 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 2 | 2001 | 13 | 0.060 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2007 | 458 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2017 | 2541 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2017 | 4861 | 0.060 |
Why?
|
| Azacitidine | 2 | 2017 | 336 | 0.060 |
Why?
|
| Tumor Burden | 1 | 2011 | 1906 | 0.060 |
Why?
|
| Mandible | 1 | 1989 | 759 | 0.060 |
Why?
|
| Thiazolidinediones | 2 | 2005 | 461 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2011 | 1319 | 0.060 |
Why?
|
| Fear | 2 | 2022 | 1493 | 0.050 |
Why?
|
| Collagen | 1 | 1991 | 2645 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2017 | 17142 | 0.050 |
Why?
|
| Thyroglobulin | 2 | 1999 | 111 | 0.050 |
Why?
|
| Animals | 19 | 2021 | 169285 | 0.050 |
Why?
|
| Liver | 2 | 2016 | 7578 | 0.050 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2006 | 748 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2001 | 97 | 0.050 |
Why?
|
| Hospitalization | 1 | 2021 | 10840 | 0.050 |
Why?
|
| Melanoma | 1 | 2000 | 5706 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2001 | 2204 | 0.050 |
Why?
|
| Vasodilation | 3 | 2005 | 967 | 0.050 |
Why?
|
| Glucose Clamp Technique | 4 | 2006 | 263 | 0.050 |
Why?
|
| Exercise | 1 | 2018 | 5954 | 0.050 |
Why?
|
| Hyperinsulinism | 2 | 2001 | 402 | 0.050 |
Why?
|
| DNA-Binding Proteins | 2 | 2012 | 9617 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2017 | 4754 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 4 | 2002 | 6124 | 0.050 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2007 | 1124 | 0.050 |
Why?
|
| Cell Survival | 1 | 2011 | 5789 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2014 | 3479 | 0.040 |
Why?
|
| Materials Testing | 3 | 1993 | 873 | 0.040 |
Why?
|
| Prognosis | 1 | 2021 | 30009 | 0.040 |
Why?
|
| Risk Factors | 5 | 2020 | 74944 | 0.040 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2000 | 147 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 2006 | 1676 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2007 | 1802 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2002 | 622 | 0.040 |
Why?
|
| Guinea Pigs | 1 | 2001 | 1309 | 0.040 |
Why?
|
| Adenoviridae | 2 | 2003 | 1093 | 0.040 |
Why?
|
| Awareness | 1 | 2024 | 653 | 0.040 |
Why?
|
| Metformin | 2 | 2005 | 909 | 0.040 |
Why?
|
| Diabetic Angiopathies | 1 | 2005 | 806 | 0.040 |
Why?
|
| Antineoplastic Agents | 3 | 2009 | 13677 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2000 | 183 | 0.040 |
Why?
|
| Interferon-gamma | 2 | 2017 | 3161 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2006 | 2857 | 0.040 |
Why?
|
| Body Image | 1 | 2024 | 646 | 0.040 |
Why?
|
| Cell Division | 3 | 2004 | 4477 | 0.040 |
Why?
|
| Cells | 1 | 2000 | 166 | 0.040 |
Why?
|
| Plasmids | 2 | 2021 | 2269 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 1737 | 0.040 |
Why?
|
| Microdissection | 2 | 2011 | 150 | 0.040 |
Why?
|
| Acetylcholine | 3 | 2006 | 629 | 0.040 |
Why?
|
| Mice | 9 | 2016 | 82049 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2007 | 1422 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2007 | 11930 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2021 | 54924 | 0.040 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 1999 | 91 | 0.040 |
Why?
|
| Vasodilator Agents | 2 | 2005 | 990 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2007 | 8316 | 0.040 |
Why?
|
| Diet, Reducing | 1 | 2021 | 487 | 0.040 |
Why?
|
| Arginine | 1 | 2002 | 932 | 0.040 |
Why?
|
| Parathyroid Neoplasms | 1 | 1999 | 244 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 4 | 1996 | 945 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2019 | 24318 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 11095 | 0.040 |
Why?
|
| Capillary Permeability | 1 | 2001 | 772 | 0.040 |
Why?
|
| Anxiety | 2 | 2024 | 4672 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2011 | 8142 | 0.040 |
Why?
|
| Hypertension | 4 | 2000 | 8616 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2023 | 1667 | 0.040 |
Why?
|
| Cell Cycle | 1 | 2006 | 2934 | 0.040 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2017 | 36 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2007 | 2211 | 0.040 |
Why?
|
| Edema | 1 | 2001 | 765 | 0.040 |
Why?
|
| Ascorbic Acid | 1 | 2000 | 658 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2000 | 899 | 0.040 |
Why?
|
| Standard of Care | 1 | 2021 | 568 | 0.030 |
Why?
|
| Biopsy, Needle | 2 | 1999 | 1623 | 0.030 |
Why?
|
| Receptors, Interferon | 1 | 2017 | 115 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 1750 | 0.030 |
Why?
|
| Cysteine | 1 | 2021 | 897 | 0.030 |
Why?
|
| Stem Cells | 2 | 2008 | 3538 | 0.030 |
Why?
|
| Endothelial Cells | 2 | 2007 | 3589 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 258 | 0.030 |
Why?
|
| Latex | 1 | 1996 | 49 | 0.030 |
Why?
|
| Gloves, Surgical | 1 | 1996 | 24 | 0.030 |
Why?
|
| Paclitaxel | 2 | 2002 | 1733 | 0.030 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 1996 | 33 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2000 | 2939 | 0.030 |
Why?
|
| Body Constitution | 3 | 2001 | 273 | 0.030 |
Why?
|
| Adenoma | 2 | 1999 | 2159 | 0.030 |
Why?
|
| RNA, Messenger | 4 | 2010 | 12801 | 0.030 |
Why?
|
| Dogs | 1 | 2021 | 3845 | 0.030 |
Why?
|
| United States | 2 | 2021 | 73039 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2019 | 2661 | 0.030 |
Why?
|
| Interferon Regulatory Factors | 1 | 2017 | 271 | 0.030 |
Why?
|
| Fasting | 2 | 2018 | 1610 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2017 | 687 | 0.030 |
Why?
|
| Rats | 5 | 2011 | 23782 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2017 | 515 | 0.030 |
Why?
|
| Epithelial Cells | 2 | 2007 | 3703 | 0.030 |
Why?
|
| Food | 1 | 2000 | 768 | 0.030 |
Why?
|
| Dentistry | 1 | 1996 | 117 | 0.030 |
Why?
|
| Thyroid Neoplasms | 2 | 1999 | 2360 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 2909 | 0.030 |
Why?
|
| Stem Cell Transplantation | 1 | 2004 | 1599 | 0.030 |
Why?
|
| Hemangioma | 1 | 2000 | 727 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 2 | 2000 | 3620 | 0.030 |
Why?
|
| Ligation | 1 | 2016 | 446 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 2000 | 1207 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2004 | 1789 | 0.030 |
Why?
|
| Animals, Newborn | 2 | 2011 | 2683 | 0.030 |
Why?
|
| Protease Inhibitors | 2 | 2011 | 751 | 0.030 |
Why?
|
| Medical Audit | 1 | 2016 | 454 | 0.030 |
Why?
|
| Patient Satisfaction | 2 | 2017 | 3490 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2016 | 526 | 0.030 |
Why?
|
| Dental Bonding | 2 | 1991 | 37 | 0.030 |
Why?
|
| Eosinophilia | 1 | 1999 | 556 | 0.030 |
Why?
|
| Bilirubin | 1 | 2016 | 438 | 0.030 |
Why?
|
| Hypertrophy | 1 | 2016 | 562 | 0.030 |
Why?
|
| Virus Replication | 2 | 2012 | 2458 | 0.030 |
Why?
|
| Time Factors | 5 | 2017 | 40220 | 0.030 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2000 | 1494 | 0.030 |
Why?
|
| Liver Failure | 1 | 2016 | 252 | 0.030 |
Why?
|
| Research | 1 | 2022 | 1979 | 0.030 |
Why?
|
| Hypophysectomy | 1 | 1993 | 114 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 4585 | 0.030 |
Why?
|
| Portal Vein | 1 | 2016 | 435 | 0.030 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 1996 | 249 | 0.030 |
Why?
|
| Treatment Outcome | 5 | 2021 | 65379 | 0.030 |
Why?
|
| Hyperprolactinemia | 1 | 1994 | 124 | 0.030 |
Why?
|
| Acute Disease | 2 | 2002 | 7243 | 0.030 |
Why?
|
| Thyroiditis, Suppurative | 1 | 1992 | 7 | 0.030 |
Why?
|
| Thyroiditis, Subacute | 1 | 1992 | 11 | 0.030 |
Why?
|
| Vaccines, Virus-Like Particle | 1 | 2012 | 44 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 15949 | 0.030 |
Why?
|
| Diagnosis-Related Groups | 1 | 2014 | 445 | 0.030 |
Why?
|
| Macrophages | 1 | 2007 | 5802 | 0.020 |
Why?
|
| Metabolomics | 1 | 2021 | 1674 | 0.020 |
Why?
|
| Repressor Proteins | 1 | 2003 | 2982 | 0.020 |
Why?
|
| Models, Theoretical | 2 | 2001 | 3573 | 0.020 |
Why?
|
| Chorionic Villi | 1 | 1992 | 53 | 0.020 |
Why?
|
| Microscopy | 1 | 2017 | 909 | 0.020 |
Why?
|
| Cushing Syndrome | 1 | 1993 | 241 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2018 | 2107 | 0.020 |
Why?
|
| Registries | 2 | 2020 | 8375 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 1837 | 0.020 |
Why?
|
| Dental Leakage | 1 | 1991 | 5 | 0.020 |
Why?
|
| Dentin Permeability | 1 | 1991 | 1 | 0.020 |
Why?
|
| Decidua | 1 | 1992 | 82 | 0.020 |
Why?
|
| Smear Layer | 1 | 1991 | 4 | 0.020 |
Why?
|
| Dentin Sensitivity | 1 | 1991 | 5 | 0.020 |
Why?
|
| Body Mass Index | 4 | 2021 | 13053 | 0.020 |
Why?
|
| Reference Values | 3 | 2006 | 4939 | 0.020 |
Why?
|
| Glycerolphosphate Dehydrogenase | 1 | 2011 | 40 | 0.020 |
Why?
|
| Composite Resins | 1 | 1991 | 72 | 0.020 |
Why?
|
| Signal Transduction | 3 | 2017 | 23648 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2021 | 12466 | 0.020 |
Why?
|
| Malate Dehydrogenase | 1 | 2011 | 40 | 0.020 |
Why?
|
| U937 Cells | 1 | 2011 | 260 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 1999 | 1738 | 0.020 |
Why?
|
| Caregivers | 1 | 2023 | 2302 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 1999 | 2914 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2016 | 2627 | 0.020 |
Why?
|
| Organ Size | 1 | 2016 | 2267 | 0.020 |
Why?
|
| Apoptosis | 3 | 2016 | 9527 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2012 | 739 | 0.020 |
Why?
|
| Surface Properties | 1 | 1993 | 1166 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2011 | 251 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2012 | 491 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2011 | 328 | 0.020 |
Why?
|
| Solutions | 1 | 1991 | 409 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2012 | 912 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 2 | 2000 | 72 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2006 | 11677 | 0.020 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2012 | 450 | 0.020 |
Why?
|
| Thyroxine | 1 | 1994 | 665 | 0.020 |
Why?
|
| Deuterium | 2 | 2000 | 106 | 0.020 |
Why?
|
| Prevalence | 2 | 2020 | 15869 | 0.020 |
Why?
|
| Weight Loss | 1 | 2021 | 2721 | 0.020 |
Why?
|
| Receptors, Vitronectin | 2 | 2000 | 48 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 8542 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2011 | 414 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2010 | 5028 | 0.020 |
Why?
|
| Hypothyroidism | 1 | 1994 | 667 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 8648 | 0.020 |
Why?
|
| Kinetics | 3 | 2001 | 6330 | 0.020 |
Why?
|
| Virus Internalization | 1 | 2012 | 503 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2006 | 2230 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2012 | 549 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2012 | 1760 | 0.020 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2012 | 925 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2009 | 210 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2000 | 4541 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2012 | 729 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2017 | 1596 | 0.020 |
Why?
|
| Neoplasm Transplantation | 2 | 2002 | 2014 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1999 | 3474 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 1344 | 0.020 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2007 | 97 | 0.020 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1992 | 519 | 0.020 |
Why?
|
| Mouth | 1 | 1989 | 383 | 0.020 |
Why?
|
| Regression Analysis | 3 | 2001 | 6340 | 0.020 |
Why?
|
| Embryonic Development | 1 | 1992 | 724 | 0.020 |
Why?
|
| Hyperplasia | 1 | 1989 | 1151 | 0.020 |
Why?
|
| AIDS Vaccines | 1 | 2012 | 900 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 8052 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2011 | 733 | 0.020 |
Why?
|
| Inflammation | 1 | 2006 | 10873 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2011 | 1251 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2007 | 558 | 0.020 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2006 | 279 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 21207 | 0.010 |
Why?
|
| Pituitary Neoplasms | 1 | 1993 | 1322 | 0.010 |
Why?
|
| Disease Progression | 1 | 2021 | 13668 | 0.010 |
Why?
|
| Depression | 1 | 2024 | 8230 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2006 | 1769 | 0.010 |
Why?
|
| Binding Sites | 1 | 2012 | 6019 | 0.010 |
Why?
|
| Cell Communication | 1 | 2011 | 1660 | 0.010 |
Why?
|
| Flow Cytometry | 2 | 2007 | 5902 | 0.010 |
Why?
|
| Hematocrit | 1 | 2005 | 623 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 14783 | 0.010 |
Why?
|
| Receptor, Insulin | 1 | 2007 | 839 | 0.010 |
Why?
|
| Glucose Intolerance | 1 | 2007 | 579 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2007 | 1353 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2001 | 22290 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 6512 | 0.010 |
Why?
|
| Lung | 1 | 2001 | 10101 | 0.010 |
Why?
|
| Antibodies, Neutralizing | 1 | 2012 | 2009 | 0.010 |
Why?
|
| RNA Interference | 1 | 2011 | 2832 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 3833 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 12077 | 0.010 |
Why?
|
| Movement | 1 | 1989 | 1490 | 0.010 |
Why?
|
| Lasers | 1 | 2006 | 952 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 2012 | 10266 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 3806 | 0.010 |
Why?
|
| Muscles | 1 | 2007 | 1582 | 0.010 |
Why?
|
| DNA Primers | 1 | 2006 | 2828 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 7477 | 0.010 |
Why?
|
| Extraembryonic Membranes | 1 | 2002 | 37 | 0.010 |
Why?
|
| Deuterium Oxide | 1 | 2001 | 34 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2005 | 939 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 4913 | 0.010 |
Why?
|
| Immune System | 1 | 2007 | 800 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 12543 | 0.010 |
Why?
|
| Cell Line | 2 | 2007 | 15602 | 0.010 |
Why?
|
| Logistic Models | 1 | 2016 | 13290 | 0.010 |
Why?
|
| Cell Separation | 1 | 2006 | 1728 | 0.010 |
Why?
|
| Glycogen | 1 | 2001 | 252 | 0.010 |
Why?
|
| Body Composition | 2 | 2000 | 2462 | 0.010 |
Why?
|
| Sarcoma, Experimental | 1 | 2000 | 117 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2000 | 220 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2017 | 7876 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2002 | 749 | 0.010 |
Why?
|
| Protein Binding | 1 | 2012 | 9343 | 0.010 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2007 | 1361 | 0.010 |
Why?
|
| Tritium | 1 | 2000 | 707 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2006 | 1165 | 0.010 |
Why?
|
| Length of Stay | 1 | 2014 | 6498 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2000 | 150 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2007 | 2634 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2000 | 6568 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2007 | 1854 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2000 | 363 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2007 | 1801 | 0.010 |
Why?
|
| Endothelial Growth Factors | 1 | 2002 | 672 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 15453 | 0.010 |
Why?
|
| Astrocytes | 1 | 2007 | 1350 | 0.010 |
Why?
|
| Receptors, Fibronectin | 1 | 1999 | 37 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2008 | 2575 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2000 | 375 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2000 | 866 | 0.010 |
Why?
|
| Lymphokines | 1 | 2002 | 925 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2000 | 1553 | 0.010 |
Why?
|
| Radiography | 1 | 1989 | 6986 | 0.010 |
Why?
|
| Lipolysis | 1 | 1999 | 211 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 1999 | 425 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2007 | 2451 | 0.010 |
Why?
|
| Adipose Tissue | 2 | 2000 | 3334 | 0.010 |
Why?
|
| Hyperparathyroidism | 1 | 1999 | 339 | 0.010 |
Why?
|
| Tunica Intima | 1 | 2000 | 459 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2006 | 3428 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2009 | 3214 | 0.010 |
Why?
|
| Models, Animal | 1 | 2004 | 2122 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2000 | 1500 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2000 | 1989 | 0.010 |
Why?
|
| Growth Substances | 1 | 1999 | 760 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 1999 | 769 | 0.010 |
Why?
|
| Body Weight | 1 | 2006 | 4627 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2006 | 3229 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2000 | 1169 | 0.010 |
Why?
|
| Algorithms | 1 | 2016 | 14164 | 0.010 |
Why?
|
| Mutation | 1 | 2000 | 30237 | 0.010 |
Why?
|
| Receptors, Virus | 1 | 1999 | 651 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2000 | 1680 | 0.010 |
Why?
|
| Regeneration | 1 | 2004 | 1524 | 0.010 |
Why?
|
| Stromal Cells | 1 | 2000 | 1337 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 4355 | 0.010 |
Why?
|
| Cattle | 1 | 2000 | 3819 | 0.010 |
Why?
|
| Medical Records | 1 | 2000 | 1410 | 0.010 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 1994 | 139 | 0.010 |
Why?
|
| Neck | 1 | 1999 | 736 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2006 | 3858 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 1999 | 14729 | 0.010 |
Why?
|
| ACTH Syndrome, Ectopic | 1 | 1993 | 30 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 1406 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 3403 | 0.010 |
Why?
|
| Quality Control | 1 | 1996 | 836 | 0.010 |
Why?
|
| Thyroidectomy | 1 | 1999 | 913 | 0.010 |
Why?
|
| Parathyroid Hormone | 1 | 1999 | 1804 | 0.010 |
Why?
|
| Hypopharynx | 1 | 1992 | 53 | 0.010 |
Why?
|
| Aorta | 1 | 2000 | 2045 | 0.010 |
Why?
|
| Transfection | 1 | 2000 | 5756 | 0.010 |
Why?
|
| Prolactin | 1 | 1994 | 627 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2003 | 5797 | 0.010 |
Why?
|
| Phosphoric Acids | 1 | 1991 | 19 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1993 | 619 | 0.010 |
Why?
|
| Oxalic Acid | 1 | 1991 | 20 | 0.010 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 1996 | 465 | 0.010 |
Why?
|
| Dental Enamel | 1 | 1991 | 61 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 1999 | 13013 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2002 | 3517 | 0.010 |
Why?
|
| Pharyngitis | 1 | 1992 | 222 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2000 | 2649 | 0.010 |
Why?
|
| Thyrotropin | 1 | 1993 | 834 | 0.010 |
Why?
|
| Pregnancy | 1 | 1992 | 30255 | 0.010 |
Why?
|
| Up-Regulation | 1 | 1999 | 4149 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1991 | 584 | 0.000 |
Why?
|
| Abscess | 1 | 1992 | 606 | 0.000 |
Why?
|
| Skin | 1 | 2002 | 4505 | 0.000 |
Why?
|
| Risk | 1 | 2000 | 9613 | 0.000 |
Why?
|
| Streptococcal Infections | 1 | 1992 | 619 | 0.000 |
Why?
|
| Biocompatible Materials | 1 | 1996 | 1703 | 0.000 |
Why?
|
| Calcium | 1 | 1999 | 5792 | 0.000 |
Why?
|
| Ultrasonography | 1 | 1999 | 6004 | 0.000 |
Why?
|
| Blood Pressure | 1 | 2001 | 8543 | 0.000 |
Why?
|
| Hydrocortisone | 1 | 1993 | 1841 | 0.000 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 18349 | 0.000 |
Why?
|
| Child | 1 | 1989 | 80917 | 0.000 |
Why?
|
| Recurrence | 1 | 1992 | 8509 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 2000 | 39354 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 1999 | 15662 | 0.000 |
Why?
|